AstraZeneca has introduced digital health solutions into clinical trials, demonstrating improved patient experience, accelerated timelines and reduced costs.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Thakur, S. & Lahiry, S. Perspect Clin. Res. 12, 184–188 (2021).
Naidoo, N. et al. BMC Med. 18, 6 (2020).
Inan, O. T. et al. npj Digital Med. 3, 101 (2020).
Johannson, K. A. et al. Eur. Resp. J. 50, 1602406 (2017).
Basch, E. et al. JAMA 318, 197–198 (2017).
Basch, E. et al. JAMA 327, 2413–2422 (2022).
Rosa, C. et al. Contemp. Clin. Trials 100, 106219 (2021).
Cook, D. et al. Nat. Rev. Drug Discov. 13, 419–431 (2014).
Morgan, P. et al. Nat. Rev. Drug Discov. 17, 167–181 (2018).
Lea, H. et al. Eur. Heart J. 42, ehab724.3061 (2021).
Vogelmeier, C. F. et al. Respir. Med. 173, 106175 (2020).
De Soyza, A. & Calverley, P. M. A. Eur. Resp. J. 45, 1692 (2015).
Garon, E. B. J. et al. J. Thorac. Oncol. 16, S892–S893 (2021).
Spira, A. L. et al. J. Thorac. Oncol. 16, S106–S107 (2021).
O’Brien, C. P. Can. Fam. Physician 55, 891–892 (2009).
Acknowledgements
The authors thank the investigators for their hard work and innovation as part of the DAPA-MI, CRESCENDO and TROPION-PanTumor01trials and acknowledge the contributions of AstraZeneca therapeutic area leads, clinical teams, development operations and technology teams, as without cross-functional collaboration the implementation of new innovative designs would not be possible. The research described in this paper was funded and undertaken by AstraZeneca PLC. Medical writing support was provided by E. Morton of Ashfield MedComms, an Inizio company, which was in accordance with Good Publication Practice (GPP) 2022 guidelines and funded by AstraZeneca.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.O.D., M.B., E.B., R.H., S.G., C.M., A C., M.N.P. and S.G. are employed by AstraZeneca; E.H. is employed by Emmette Hutchison LLC. The authors declare no further conflicts of interests.
Rights and permissions
About this article
Cite this article
Durán, C.O., Bonam, M., Björk, E. et al. Implementation of digital health technology in clinical trials: the 6R framework. Nat Med 29, 2693–2697 (2023). https://doi.org/10.1038/s41591-023-02489-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02489-z
